Date: 2012-04-12
Type of information: R&D agreement
Compound: toxic protein warhead for the next generation of antibody drug conjugates (ADCs)
Company: Antitope (UK) Research Corporation Technologies (USA)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism:
Disease:
Details: * On April 12, 2012, Antitope has announced a research agreement with Research Corporation Technologies to re-engineer a toxic protein warhead for the next generation of antibody drug conjugates (ADCs) using it\'s proprietary Composite Protein technology. The resulting \"deimmunised\" protein is expected to have a range of therapeutic applications especially in the treatment of cancers. Under the agreement, Antitope will be eligible for research fees and subsequent milestone and royalty payments.
Financial terms:
Latest news:
